Annotation Detail
Information
- Associated Genes
- VHL
- Associated Variants
-
VHL LOSS-OF-FUNCTION
VHL LOSS-OF-FUNCTION - Associated Disease
- renal cell carcinoma
- Source Database
- CIViC Evidence
- Description
- A meta-analysis to evaluate the association between the VHL alteration and clinical outcomes in patients with RCC. There were six studies including a total of 633 patients: 244 patients who received anti-VEGF therapy in the predictive value analysis and 419 in the prognostic value analysis. 410 (61.8%) had VHL alteration. The meta-analysis showed no association between the VHL gene alteration and ORR or PFS, as well as no correlation to OS. VEGFR inhibition included: Sunitinib, Sorafenib, Axitinib, Pazopanib, Bevacizumab.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/4832
- Gene URL
- https://civic.genome.wustl.edu/links/genes/58
- Variant URL
- https://civic.genome.wustl.edu/links/variants/160
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Renal Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Anti-VEGF Monoclonal Antibody
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 28103578
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Anti-VEGF Monoclonal Antibody | Resitance or Non-Reponse | true |